The application of adverse drug reaction data to drug choice decisions made by pharmacy and therapeutics committees. An australian perspective

Drug Safety

Volumn 18, Issue 3, 1998, Pages 153-159

  Weekes, Lynn M ^a   Day, Richard O ^b  

^a New S Wales Therapeut Assess G   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; DATA ANALYSIS; DATA BASE; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG INFORMATION; DRUG SAFETY; DRUG TOXICITY; ERROR; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH ECONOMICS; MEDICAL DECISION MAKING; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AUSTRALIA; DATA INTERPRETATION, STATISTICAL; FORMULARIES, HOSPITAL; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE;

EID: 0031913619     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199818030-00001     Document Type: Review

References (19)

1. Henriksen HH. A social scientific view on the development of Pharmacy and Therapeutics Committees. Soc Sci Med 1982; 16: 753-7
2. Editor's roundtable. Current formulas for P&T Committee success (Part 1). Hosp Formul 1987; 22: 288
3. Wilson JV, Hawkey CJ. Drug and Therapeutics Committees in the UK: 1981-1987. Br J Pharm Pract 1990; Jun: 198-205
4. Bochner F, Martin ED, Burgess NG, et al. Drug rationing in a teaching hospital: a method to assign priorities. BMJ 1994; 308: 901-5
5. Weekes LM, Brooks C. Drug and Therapeutics Committees in Australia: expected and actual performance. Br J Clin Pharmacol 1996; 42: 551-7
6. Curtiss FR. Drug formularies provide a path to best care. Am J Health Syst 1996; 53: 2201-3
7. Rucker TD, Schiff G. Drug formularies: myths-in-formation. Hosp Pharm 1991; 26: 507-21
8. Anon. Current formulary decision-making strategies and new factor influencing the process: results of our national survey. Formulary 1995; 30: 462-71
9. Glaeske G. Quality control of drug prescriptions by positive lists - the European Formulary. Clin Pharmacol Ther 1994; 32: 403-8
10. Summers KH, Szeinbach SL. Formularies: the role of pharmacy-and-therapeutics (P&T) Committees. Clin Ther 1993; 15: 433-41
11. Dunford RW. Organisational behaviour: an organisational analysis perspective. Sydney: Addison-Wesley, 1992
12. Schumacher GE. Multiattribute evaluation in formulary decision making as applied to calcium channel blockers. Am J Hosp Pharm 1991; 48: 301-8
13. Denig P, Haaijer-Ruskamp FM, Wesseling H, et al. Drug expectations and drug choices of hospital physicians. J Intern Med 1993; 234: 155-63
14. Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines. BMJ 1995; 311: 1003-6
15. Kresel JJ, Hutchings HC, MacKay DN, et al. Application of decision analysis to drug selection for formulary addition. Hosp Formul 1987; 22: 658-76
16. Eriksen S, Keller LR. A multivariate-utility-function approach to weighing the risks and benefits of pharmaceutical agents. Med Decis Making 1993; 13: 118-25
17. Bates DW, Boyle DL, Van der Vliet MB, et al. Relationship between medication errors and adverse drug reactions. J Gen Intern Med 1995; 10: 199-205
18. O'Hara DA, Carson NJ. Reporting of adverse events in hospitals in Victoria, 1994-1995. Med J Aust 1997; 166: 460-3
19. Weekes LM, Brooks C, Day RO, et al. Indicators for drug and therapeutics committees. Br J Clin Pharmacol 1998; 45: 1-6